Capecitabine: From Mechanism to Clinical Success in Colon Cancer

Abstract: Capecitabine, an oral prodrug, inhibits DNA synthesis, which is how cancer cells are attacked. It undergoes enzymatic conversion in the body to 5-fluorouracil (5-FU), a well-known anticancer agent. Numerous studies have examined its use in the treatment of colon cancer, and both monotherapy and combination regimens have shown potential. Regarding capecitabine's role in colon cancer treatment, this study aims to provide a comprehensive overview, including the drug's mechanism of action, conversion to 5-FU, formulations, and preclinical, clinical, and patent research. Data from Google Patents, Science Direct, Clinical Trials.gov, Google Scholar, and PubMed were gathered to offer a thorough examination of the drug's effect on colon cancer therapy. Preclinical research has shown its synergistic effects with various chemotherapeutic medications or targeted therapies, offering promising opportunities for combination therapy regimens. So, a clinical study indicates that Capecitabine is a very successful therapy for colon cancer patients, improving their prognosis and slowing the growth of their tumors. The bioavailability and patient compliance of this medication have improved as a result of advancements in formulation technology. Patents have facilitated the development of innovative formulations and delivery methods, thereby increasing the therapeutic potential of the medicine. Capecitabine's targeted action and efficient oral distribution make it a mainstay in the treatment of colon cancer. It is an essential component of colon cancer treatment, and its use is growing due to increased research and its promising potential in personalized medicine techniques, which will benefit patients worldwide.